- Investing Ideas
- Global Pharmaceuticals & Biotech Undervalued based on future growth
Global Pharmaceuticals & Biotech Undervalued based on future growth
Results
43
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
43 companies
Daewon Pharmaceutical
Market Cap: ₩167.4b
A pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea.
A003220
₩7,810.00
7D
-1.9%
1Y
-40.2%
Daihan PharmaceuticalLtd
Market Cap: ₩155.8b
Engages in the manufacture and sale of therapeutic drugs in South Korea.
A023910
₩26,500.00
7D
-0.7%
1Y
-10.9%
Macrogen
Market Cap: ₩135.4b
Provides precision medicine and bio-engineering healthcare services in Korea and internationally.
A038290
₩12,490.00
7D
-2.8%
1Y
-20.5%
Rallybio
Market Cap: US$89.4m
A clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
RLYB
US$16.83
7D
-1.0%
1Y
261.6%
Hyphens Pharma International
Market Cap: S$112.8m
Operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally.
1J5
S$0.36
7D
0%
1Y
14.1%
Labiana Health
Market Cap: €52.3m
Develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally.
LAB
€6.35
7D
0%
1Y
62.0%
Actinium Pharmaceuticals
Market Cap: US$34.6m
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
ATNM
US$1.10
7D
4.8%
1Y
-38.5%